Filtered By:
Specialty: Cardiology
Source: Atherosclerosis
Drug: Clopidogrel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 27 results found since Jan 2013.
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04078737.PMID:37548009 | DOI:10.1161/STROKEAHA.122.042233
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Xuewei Xie Jing Jing Xia Meng S Claiborne Johnston Philip M Bath Zixiao Li Xingquan Zhao Liping Liu Yilong Wang Qin Xu Anxin Wang Yong Jiang Hao Li Yongjun Wang CHANCE-2 Investigators Source Type: research
Middle Cerebral Artery Dissection: A Report of Two Cases With Treatments and Outcomes
Cureus. 2023 May 29;15(5):e39632. doi: 10.7759/cureus.39632. eCollection 2023 May.ABSTRACTIn the present report, we describe two cases of right-sided M1 segment middle cerebral artery dissection in a 51-year-old Asian female and in a 28-year-old Caucasian male patient with no previous history of ischemic stroke or known intracranial atherosclerosis presenting with acute unilateral headache progressing to severe multifocal hemispheric infarction with nearly complete one-sided motor paralysis. In both patients, a middle cerebral artery dissection was detected on angiography; they were given exclusively medical therapy: patie...
Source: Atherosclerosis - June 30, 2023 Category: Cardiology Authors: Giulio Papiri Stefano Bruni Emanuele Puca Sandro Sanguigni Matteo Marcucci Source Type: research
Optimization of secondary prevention in patients with high-risk atherothrombotic ischemic stroke or transient ischemic attacks
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(6):36-43. doi: 10.17116/jnevro202312306136.ABSTRACTHigh and very high risk atherothrombotic ischemic stroke (ATIS) includes patients with severe extracranial atherosclerosis, any intracranial atherosclerosis, and aortic arch atheromatosis. The article discusses the most effective approaches to medical short- and long-term secondary prevention of ATIS, major vascular events and death, based on the results of modern research and current clinical guidelines. Clinical studies of recent years have proven the possibility of individualization and intensification of secondary preventi...
Source: Atherosclerosis - June 29, 2023 Category: Cardiology Authors: A A Kulesh S N Yanishevskiy D A Demin L I Syromyatnikova O I Vinogradov Source Type: research
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines
Curr Neurol Neurosci Rep. 2023 Apr 11. doi: 10.1007/s11910-023-01266-2. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Stroke is a leading cause of death and disability worldwide. The annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the United States, of which 87% are ischemic in nature. In addition to the management of modifiable high-risk factors to reduce the risk of recurrent stroke, antithrombotic agents (antiplatelets and anticoagulants) play an important role in secondary stroke prevention. This review will discuss the published literature on the use of antiplatelets and antic...
Source: Atherosclerosis - April 10, 2023 Category: Cardiology Authors: Kunal Bhatia Lindsey M Ladd Kelsey H Carr Mario Di Napoli Jeffrey L Saver Louise D McCullough Maryam Hosseini Farahabadi Diana L Alsbrook Archana Hinduja Jorge G Ortiz Garcia Sara Y Sabbagh Alibay Jafarli Afshin A Divani Source Type: research
Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III
CONCLUSIONS: This integrated analysis supports the findings of PRASTRO-III. Prasugrel is a promising treatment that results in a numerical reduction in the composite incidence of ischemic stroke, MI, and death from other vascular causes in patients with ischemic stroke who are at a high risk of stroke recurrence. No major safety issues were observed for prasugrel.PMID:37011599 | DOI:10.1159/000529149
Source: Atherosclerosis - April 3, 2023 Category: Cardiology Authors: Takanari Kitazono Masahiro Kamouchi Yuji Matsumaru Toshiaki Shirai Atsushi Takita Takeshi Kuroda Kazumi Kimura Source Type: research
Rationale and design of a randomised double-blind 2 ×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES)
CONCLUSION: The INSPIRES trial will assess the efficacy and safety of intensive antiplatelet therapy and immediate intensive statin therapy begun within 72 hours of onset in decreasing the recurrent stroke at 90 days in patients with acute mild ischaemic stroke or high-risk TIA of intracranial or extracranial atherosclerosis origin.TRIAL REGISTRATION NUMBER: NCT03635749.PMID:36707080 | DOI:10.1136/svn-2022-002084
Source: Atherosclerosis - January 27, 2023 Category: Cardiology Authors: Ying Gao Yuesong Pan Shangrong Han Weiqi Chen Jing Jing Chunjuan Wang Yingying Yang Tingting Wang Xia Meng Xingquan Zhao Liping Liu Hao Li S Claiborne Johnston Pierre Amarenco Philip M Bath Yongjun Wang Yilong Wang INSPIRES Investigators Source Type: research
Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study
CONCLUSIONS: Patients suffering from cardiovascular events and mortality were characterized by prior cardiovascular events as compared to patients who did not experience any events. Antiplatelet therapy was not optimally protective despite high medication adherence, and HTPR was independently associated with the occurrence of events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.TRIAL REGISTRATION: The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial ...
Source: Atherosclerosis - January 10, 2023 Category: Cardiology Authors: B M M Kremers J H C Daemen H Ten Cate H M H Spronk B M E Mees A J Ten Cate-Hoek Source Type: research
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Atherosclerosis - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research
Treatment of progressive ischemic stroke with low ‑dose eptifibatide: A retrospective case‑control study
Exp Ther Med. 2022 Nov 22;25(1):22. doi: 10.3892/etm.2022.11721. eCollection 2023 Jan.ABSTRACTProgressive ischemic stroke (PIS) is a therapeutic challenge in clinical practice. The present retrospective study aimed to investigate the safety and effectiveness of eptifibatide in the treatment of PIS. The present study enrolled patients with PIS admitted to Xiangtan Central Hospital (Xiangtan, China) between March 2020 and March 2021 with National Institutes of Health Stroke Scale (NIHSS) progression scores of ≥2 points during the initial 72 h. Patients were then divided into two groups according to their different anti-pla...
Source: Atherosclerosis - December 23, 2022 Category: Cardiology Authors: Long Luo Jinsheng Lin Ye Deng Zhigang Li Ying Yuan Wen Zhang Source Type: research
A 28-year-old male with spontaneous coronary artery dissection complicated by apical thrombus and acute ischemic stroke: An interesting case
Radiol Case Rep. 2022 Nov 2;18(1):246-249. doi: 10.1016/j.radcr.2022.10.001. eCollection 2023 Jan.ABSTRACTSpontaneous coronary artery dissection is described as the intramural bleeding that separates the layers of an epicardial coronary artery wall, either with or without an intimal tear. Atherosclerosis, iatrogenic damage, or trauma are not linked to this syndrome. Here we present a 28-year-old male with 1 month history stroke but no any chronic disease as well family history of heart disease who presented with 2 days' duration of typical cardiac chest pain. Based on an emergency electrocardiogram that showed biphasic T-w...
Source: Atherosclerosis - November 10, 2022 Category: Cardiology Authors: Said Abdirahman Ahmed Mesut Karata ş L ütfi Öcal Mohamed Abdullahi Mohamud Ishak Ahmed Abdi Mohamed Omar Hassan Source Type: research
Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art
Stroke. 2022 Nov 3. doi: 10.1161/STROKEAHA.122.037717. Online ahead of print.ABSTRACTThere is considerable interindividual variability in the response to antiplatelet and anticoagulant therapies, and this variation may be attributable to genetic variants. There has been an increased understanding of the genetic architecture of stroke and cardiovascular disease, which has been driven by advancements in genomic technologies and this has raised the possibility of more targeted pharmaceutical treatments. Pharmacogenetics promises to use a patient's genetic profile to treat those who are more likely to benefit from a particular...
Source: Atherosclerosis - November 3, 2022 Category: Cardiology Authors: Stephanie Ross Kristi Krebs Guillaume Par é Lili Milani Source Type: research
Antiplatelets and Vascular Dementia: A Systematic Review
J Aging Res. 2022 Sep 19;2022:9780067. doi: 10.1155/2022/9780067. eCollection 2022.ABSTRACTVascular dementia (VD) is a neurocognitive disorder whose precise definition is still up for debate. VD generally refers to dementia that is primarily caused by cerebrovascular disease or impaired cerebral blood flow. It is a subset of vascular cognitive impairment, a class of diseases that relate any cerebrovascular injury as a causal or correlating factor for cognitive decline, most commonly seen in the elderly. Patients who present with both cognitive impairment and clinical or radiologic indications of cerebrovascular pathology s...
Source: Atherosclerosis - October 17, 2022 Category: Cardiology Authors: Peter Alexander Shakthi Visagan Sara Jawhar Amogh Kare Noor Issa Reem Issa Abbas Jawhar Sneha Thomas Vasavi Gorantla Source Type: research
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)
CONCLUSION: The aim of the GENPAD study is to evaluate the efficacy, safety, and cost-effectiveness of a genotype-guided antithrombotic treatment strategy compared to conventional clopidogrel treatment in PAD patients.PMID:35988587 | DOI:10.1016/j.ahj.2022.08.001
Source: Atherosclerosis - August 21, 2022 Category: Cardiology Authors: J Kranendonk L H Willems Rj van der Vijver-Coppen M Coenen E Adang R Donders C J Zeebregts Vhm Deneer Mmpj Reijnen C Kramers M C Warl é Source Type: research
